4//SEC Filing
Kurtoglu Metin 4
Accession 0001453687-24-000145
CIK 0001453687other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 4:28 PM ET
Size
16.3 KB
Accession
0001453687-24-000145
Insider Transaction Report
Form 4
Kurtoglu Metin
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2024-12-10$1.41/sh+2,901$4,090→ 53,934 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-10−2,901→ 79,099 totalExercise: $1.41Exp: 2026-11-06→ Common Stock (2,901 underlying) - Exercise/Conversion
Common Stock
2024-12-09$1.41/sh+10,763$15,176→ 61,796 total - Sale
Common Stock
2024-12-09$25.26/sh−6,224$157,236→ 55,572 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-09−10,763→ 82,000 totalExercise: $1.41Exp: 2026-11-06→ Common Stock (10,763 underlying) - Sale
Common Stock
2024-12-10$24.35/sh−2,901$70,640→ 51,033 total - Sale
Common Stock
2024-12-09$25.83/sh−4,539$117,257→ 51,033 total
Footnotes (5)
- [F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.58 to $25.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.58 to $26.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option was fully vested and exercisable upon the closing of the merger described in footnote 5.
- [F5]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.
Documents
Issuer
Cartesian Therapeutics, Inc.
CIK 0001453687
Entity typeother
Related Parties
1- filerCIK 0002000284
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 4:28 PM ET
- Size
- 16.3 KB